7:00 a.m. Registration, Continental Breakfast, and Exhibits

7:50 a.m. Welcome and Opening Remarks, Invocation
Jay Geoghagan, MD, FACC
David Jones, MD, FACC
Steve Greer, MD, FACC, FACP

8:00 a.m. Hypertension
Dwight Chrisman, MD, FACC

8:30 a.m. Aortic Aneurysm Diagnosis and Management
Wesley Fiser, MD, FACC

9:00 a.m. DAPT after PCI
Tom Conley, MD, FACC, FSCAI

9:30 a.m. Morning Break and Exhibits

9:45 a.m. Exercise and Sports Cardiology
Jay Geoghagan, MD, FACC

10:15 a.m. Non-Surgical Structural Options – What the PCP Needs to Know
Evan Watts, MD, FACC

10:45 a.m. Women and Heart Disease
Christen Johnson, MD

11:15 a.m. Management of Chronic Coronary Disease
Charles Caldwell, MD, FACC

11:45 a.m. Lunch and Exhibits

12:45 p.m. HFrEF
Patrick Campbell, MD, FACC

1:15 p.m. HFpEF
Bernard Gojer, MD, FACC

1:45 p.m. ECG Review
Jeff Neuhauser, DO, FACC, FHRS

2:15 p.m. Afternoon Break and Exhibits

2:30 p.m. Afib
Breck Sandvall, MD

3:00 p.m. Nutrition
Alex Orsini, MD, FACC

3:30 p.m. Adjourn

Objectives

• Review ACC/AHA guidelines related to the treatment of poorly controlled hypertension.
• Review options for hypertension management.
• Discuss types of Aortopathy.
• Review known causes of Aortopathy.
• Discuss the appropriate duration of dual antiplatelet therapy after coronary stenting.
• Review the data for short- and long-term dual anti-platelet therapy.
• Discuss sports recommendations in post-COVID patients.
• Know the rationale and suggested use of the AHA/ACC Eligibility and Disqualification Recommendations for Competitive Athletes.
• Review the current technological advances in the interventional management ofstructural heart diseases, including minimally invasive heart valve interventionson aortic, mitral and tricuspid disease.
• Discuss improvements to safety, quality and patient satisfaction surroundingnon-surgical structural procedures.
• Discuss risk factors for Women with known coronary artery disease.
• Evaluate treatment options for Women with known coronary artery disease.
• Explain how managing health behaviors and risk factors are an important aspectof lowering the risk of cardiovascular disease.
• Discuss exercise strategies for patients with known cardiac disease.
• Review clinical treatment strategies to address patients with Heart Failure withReduced Ejection Fraction (HFrEF).
• Assess the implications of new treatments for HFrEF.
• Review clinical treatment strategies to address patients with Heart Failure withpreserved Ejection Fraction (HFpEF).
• Assess medications used to treat HFpEF.
• Review normal and abnormal ECG findings.
• Determine appropriate treatment options for specific arrhythmias.
• Review clinical literature relating to novel anticoagulant medications.
• Discuss the complications of atrial fibrillation and the reasoning behind theprescribing of an anticoagulant.
• Review Dietary trends and discuss the role they play in overall CardiovascularHealth.